Exchange Traded Concepts LLC raised its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report) by 25.1% in the first quarter, Holdings Channel reports. The fund owned 17,308 shares of the company’s stock after acquiring an additional 3,468 shares during the period. Exchange Traded Concepts LLC’s holdings in iTeos Therapeutics were worth $103,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ITOS. BVF Inc. IL bought a new stake in shares of iTeos Therapeutics in the fourth quarter valued at about $17,856,000. JPMorgan Chase & Co. lifted its holdings in shares of iTeos Therapeutics by 342.7% in the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after purchasing an additional 1,601,477 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of iTeos Therapeutics by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company’s stock valued at $9,293,000 after purchasing an additional 163,880 shares in the last quarter. Boxer Capital Management LLC bought a new stake in shares of iTeos Therapeutics in the fourth quarter valued at about $7,272,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of iTeos Therapeutics by 347.9% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company’s stock valued at $7,082,000 after purchasing an additional 716,271 shares in the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.
iTeos Therapeutics Stock Performance
ITOS opened at $10.09 on Wednesday. iTeos Therapeutics, Inc. has a 52-week low of $4.80 and a 52-week high of $18.13. The firm has a market capitalization of $386.14 million, a PE ratio of -3.32 and a beta of 1.51. The business’s 50-day simple moving average is $8.48 and its 200 day simple moving average is $7.61.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on ITOS. Leerink Partnrs lowered iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 14th. Wells Fargo & Company restated an “equal weight” rating and issued a $12.00 price target (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Wedbush lowered iTeos Therapeutics from an “outperform” rating to a “neutral” rating and boosted their price target for the company from $10.00 to $12.00 in a report on Wednesday, May 28th. Piper Sandler restated an “overweight” rating and issued a $12.00 price target (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Raymond James Financial set a $12.00 price target on iTeos Therapeutics in a report on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, iTeos Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $15.86.
Read Our Latest Report on iTeos Therapeutics
Insider Buying and Selling
In other iTeos Therapeutics news, CEO Michel Detheux sold 43,883 shares of the company’s stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total value of $439,707.66. Following the sale, the chief executive officer now owns 153,903 shares in the company, valued at $1,542,108.06. This represents a 22.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total value of $5,079,339.46. Following the completion of the sale, the insider now owns 2,108,594 shares in the company, valued at $16,995,267.64. This represents a 23.01% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,939,307 shares of company stock worth $16,202,116. Corporate insiders own 12.50% of the company’s stock.
iTeos Therapeutics Profile
iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
See Also
- Five stocks we like better than iTeos Therapeutics
- Stock Average Calculator
- 3 Hot Trades for Insiders, But Are They Good Buys for Investors?
- What is a SEC Filing?
- Why Qualcomm’s Latest Price Target Can’t Be Ignored
- Trading Halts Explained
- Analyst Sees Meta Hitting $800: What May Lead Shares to New Highs
Want to see what other hedge funds are holding ITOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iTeos Therapeutics, Inc. (NASDAQ:ITOS – Free Report).
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.